[Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo].
OBJECTIVE
To explore the enhanced cell-killing effect in vivo of herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapeutic system using tegument viral protein (VP22) intercellular trafficking.


METHODS
Human ovarian epithelial cancer cell line 3AO was infected by lentivirus containing HSV-TK and HSV-VP22-TK respectively. Tumors were induced in nude mice by subcutaneous injection of the mixture of 90% 3AO cells and 10% 3AO cells carried with HSV-TK (3AO/TK) or HSV-VP22-TK (3AO/VP22-TK). Nude mice injected with 3AO cells were used as blank control. When the volume of tumor was 150 mm(3), GCV was administered at 10 mg/kg or 50 mg/kg intraperitoneally.


RESULTS
There were significant differences, in the tumor volume and weight between 3AO/TK group and 3AO/VP22-TK group after administration of 10 mg/kg GCV (P < 0.01), and the later was more efficient than the former. But there was no significant difference after administration of 50 mg/kg GCV (P > 0.05). The tumor inhibition rates in 3AO/VP22 group and 3AO/VP22-TK group were 37.7% and 91.5% respectively after administration of 10 mg/kg GCV (P < 0.01), and were 81.8% and 96.7% respectively after administration of 50 mg/kg GCV (P > 0.05).


CONCLUSIONS
These results clearly indicate that VP22 enhances the efficiency of the suicide gene transfer, thereby increases the cell-killing effect on tumor in vivo.
Kong
Bei-hua
BH
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China.
Wang
Wen-xia
WX
Liu
Chun-sheng
CS
Ma
Dao-xin
DX
Qu
Xun
X
D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage*; D041722:Genes, Transgenic, Suicide; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology*; D013937:Thymidine Kinase / Q000235:genetics*; D014162:Transfection; D015678:Viral Structural Proteins / Q000235:genetics*
D015678:Viral Structural Proteins; C073413:herpes simplex virus type 1 protein VP22; D013937:Thymidine Kinase; D015774:Ganciclovir